Wedbush News & Analysis
9 articles
Market Mood
NICE (NICE) Shares See Price Target Cut to $100 Amid Growth Concerns
NICE Ltd. (NASDAQ:NICE) experienced a decline in billionaire stake from approximately $116.45 million in Q4 2025 to $40.58 million in Q1 2026, totaling a loss of about $75.87 million. On June 10, 2026, Wedbush lowered its price target on NICE shares from $120 to $100 while maintaining a 'Neutral' rating. This adjustment follows concerns regarding NICE's mid-single-digit revenue growth rates compared to its ambitious AI platform strategy. Analysts noted that despite promising potential in AI monetization, questions about growth and challenges remain, impacting market perceptions.
Read More
Wedbush Sees 2026 FIFA World Cup Boosting Sportsbook Performance
Wedbush has predicted that the upcoming 2026 FIFA World Cup could provide a significant upswing for a struggling sportsbook owner, although specific financial figures were not disclosed in the report. This anticipated event is important as it may lead to increased betting activity and revenue generation in the sector. The World Cup typically attracts a large audience, which could potentially benefit sportsbook operators. The impact on market performance and trading volumes remains to be analyzed as the event approaches.
Read More
Voyager Technologies (VYGR) Price Target Raised Due to Backlog Strength
Wedbush increased the price target for Voyager Technologies (VYGR) owing to a robust backlog. This adjustment reflects confidence in the company's operational capacity and future revenue potential. The financial community often closely monitors such changes as they can influence investor sentiment and trading volumes. A higher price target may also attract new investors, impacting market dynamics surrounding VYGR.
Read More
Hemab Therapeutics (HEMA) Stock Rated Outperform by Wedbush
Wedbush has initiated coverage of Hemab Therapeutics (HEMA) with an outperform rating. The market impact of this rating could potentially influence investor perception and trading behavior. However, specific financial metrics, such as P/E ratios, earnings forecasts, or price targets were not disclosed in the article. This rating positions Hemab Therapeutics favorably as it seeks to enhance its visibility in the biopharmaceutical industry.
Read More
Palantir (PLTR) Receives Strong Guidance Raise from Wedbush
Wedbush has reiterated its rating on Palantir Technologies (PLTR) following a raise in their guidance. This update signifies confidence in the company's upcoming performance and potential growth trajectory. The report highlights specific figures regarding revenue expectations and earnings forecasts but does not provide exact numbers. Analysts believe that these updates could positively influence investor sentiment and market behavior regarding PLTR shares moving forward.
Read More
MP Materials (MP) Receives $90 Price Target from Wedbush Initiation
Wedbush has initiated coverage on MP Materials (MP) with an Outperform rating and a price target of $90. The company reported full-year 2025 revenue of $224.44 million, a 10% increase year-over-year, and achieved record NdPr oxide production of 2,599 metric tons. MP Materials is the only fully integrated rare earth producer in the U.S., which is critical as the U.S. government supports domestic supply chains. Currently, MP stock is trading around $64.20, below the analyst consensus price target of $77.69.
Read More
MP Materials (MP) Stock Receives Outperform Rating from Wedbush
Wedbush has initiated coverage on MP Materials (MP) with an 'Outperform' rating, indicating expectations of strong performance. This rating suggests a positive outlook for MP in the market, potentially influencing investor interest and trading behavior. The initiation of coverage by a notable research firm can impact stock price dynamics, as investors often respond to analysts' recommendations. Market participants may look for potential catalysts related to MP's operations and performance metrics moving forward.
Read More
Tesla (TSLA) Q1 Deliveries Miss Estimates at 358,023 Vehicles
Tesla (TSLA) reported vehicle deliveries of 358,023 in Q1, falling short of Wall Street's estimate of 370,000 and resulting in a 5.42% decline in shares. This marks the second consecutive quarter of missed expectations for the company. Analyst Dan Ives from Wedbush maintained a $600 price target on TSLA, indicating a potential upside of over 65% despite soft EV demand and regulatory challenges in Europe. In addition, Tesla deployed 8.8 GWh of energy storage, below the expected 14.4 GWh, and plans to invest $20 billion in AI and robotics initiatives.
Read More
Wedbush Reiterates Tesla Stock Rating Amid Chip Factory Expansion Plans
Wedbush has maintained its rating on Tesla stock as the company plans to expand its chip manufacturing capabilities. This move aligns with Tesla's strategy to enhance its supply chain and reduce reliance on external suppliers for critical components. The stock's current price-to-earnings (P/E) ratio was not specified but is a key metric for evaluating the company's valuation. The potential increased production from the new chip factory could have significant implications for Tesla's operational efficiency and cost management.
Read More